Relapsed/Refractory Acute Leukemia
1 clinical trials · Condition
◉ Watch Relapsed/Refractory Acute Leukemia
| Record | Firm | Date |
|---|---|---|
| Expanded Access Program for Revumenib (NCT05918913) | Syndax Pharmaceuticals |
Track Relapsed/Refractory Acute Leukemia automatically
Every clearance here is in the API, with alerts when new ones post.